Tilganga Institute of Ophthalmology Gets $930 Thousand Grant to Double IOL Production

May 11, 2018: By Joan McKenna

The Tilganga Institute of Ophthalmology in Nepal has received a $930 thousand government grant ($100 million Nepalese rupees) to double production capacity for intraocular lenses, the institute announced May 10.

Tilganga said in 2017 that it produced lenses at a rate of 500 thousand per year, with a total of 4.9 million IOLs sold in more than 50 countries since it opened its doors in 1994.

Nepal native Sanduk Ruit, MD, helped found Tilganga with the mission to provide high-quality care in places considered poor by Western standards. The facility’s lenses cost as little as $3.

Ruit waives surgery fees for those unable to pay and treks to remote parts of Nepal and throughout the Himalayas to treat patients who can’t travel to the facility. Ruit and colleagues from Tilganga have traveled as far as North Korea, Cambodia, Bangladesh, Vietnam, Ethiopia, and Ghana.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility